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Background: Chemotherapy with praziquantel (PZQ) is the mainstay of schistosomiasis control. However, there are
recent concerns about tolerance or resistance to PZQ, so that monitoring its efficacy in different settings is required.
Methods: A longitudinal study was conducted to evaluate the impact of PZQ for the treatment of Schistosoma
haematobium infection among schoolchildren at Al Salamania, Central Sudan. Parasitological examinations for S.
haematobium were performed in a cohort of schoolchildren (6–15 years of age) before and 1 year after treatment
with a single dose of PZQ 40 mg/kg.
Results: Out of 562 (309 boys and 253 girls) schoolchildren recruited from three elementary schools, 420
completed one longitudinal dataset that comprised of data from two time points; baseline, and follow-up 1 year
after treatment with a single dose of PZQ 40 mg/kg for S. haematobium infection. A single dose of PZQ
significantly reduced the prevalence of S. haematobium infection by 83.3% (from 51.4% to 8.6%) and the geometric
mean intensity of infection of positive individuals by 17.0% (from 87.7 to 72.8 eggs/10 ml of urine) 1 year after
treatment. While there was no significant difference in the reduction of the prevalence of S. haematobium infection
between the gender or age groups, there was a significantly higher reduction of intensity of S. haematobium
infection among girls in comparison with boys.
Conclusion: There was a significant reduction of S. haematobium infection 1 year after PZQ treatment in this
setting.Background
Schistosomiasis is endemic in 74 countries [1], with a
bulk of the global cases (90%) residing in sub-Saharan
Africa [1,2]. In 2007, the World Health Organization
estimated 235 million cases of schistosomiasis world-
wide, with 732 million people at risk of infection in
known transmission areas [3]. In 2000, it was estimated
that 70 million people had hematuria, 32 million had
dysuria associated with Schistosoma haematobium, 18
million had major bladder wall pathology, 10 million
people had S. haematobium related renal failure; and
schistosomiasis related bladder cancer, resulting in an
estimated mortality of 150 000 people per year in sub-
Saharan Africa [4]. In Sudan the risk for S. haematobium* Correspondence: ishagadam@hotmail.com
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reproduction in any medium, provided the oris widespread in the different regions [5-7] and school
age children were at a higher risk of S. haematobium in-
fection than the other age groups [6]. Due to many fac-
tors such as higher rates of water activities, anatomical
vasculature supplying genitourinary structures and im-
munological factors, school-aged children are the group
at highest risk of contracting S. haematobium infection
[8-10].
Praziquantel (PZQ) is the mainstay of the current
strategy against schistosomiasis morbidity control [2,11].
World Health Organization (WHO) guidelines recom-
mend that in communities with schistosomiasis, and a
prevalence of 10% up to 50%, school-aged children and
high-risk groups of adults should be treated with PZQ
once every two years. In communities where prevalence
is 50% and above, the same groups should be treated
once a year [12]. Therefore mass therapy with PZQ has
been employed in many national control programmesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Sudan. Schools were the target for this policy and
treatment because of increased benefits of reducing in-
fection burdens in children compared to adults and
the ease of providing treatment [13,14]. The assess-
ment of using annual PZQ treatment for schoolchil-
dren is highly needed for both caregivers and health
planners. The present longitudinal study aimed to in-
vestigate the prevalence and intensity of S. haemato-
bium infection 1 year after treatment with PZQ among
schoolchildren at Al Salamania in central Sudan so as
to add to the body of research on the epidemiology
and effects of schistosomiasis infections among school-
children in Sudan [7,15,16].
Methods
The details of the method have been mentioned in
the previous work on Schistosoma mansoni infection
[16]. In summary, this was a continuation of the col-
laborative projects between the University of Khar-
toum and the Ministry of Health in Sudan, and it
was part of a pilot program for schistosomiasis (both
mansoni and haematobium) control that aimed at
treating schoolchildren for schistosomal infections. AFigure 1 Map of Sudan with study area and distribution of S. haematlongitudinal study was conducted at Al Salamania,
(Figure 1) which is an agricultural area in central
Sudan, during the period October 2008 to November
2009. The study was conducted in three primary
schools (for boys and girls in levels from level 1 up
to level 8, age between 1–16 years). All the children
in these three schools were included in this study.
Those students who received PZQ in the past
6 months were excluded from this study. After
obtaining permission from the Education and Health
Vice Chancellor and village head (sheikh) of this area,
the study procedure was explained to the school au-
thorities and parents/guardians of children. A longitu-
dinal dataset that comprises data from two time
points; baseline, and follow-up after 1 year was
carried-out to determine the prevalence and intensity
of urinary schistosomiasis among these schoolchildren.
Students were provided with labeled 500 ml specimen
containers and asked to provide a urine sample be-
tween 10.00 and 13.00/h. From each suspended sam-
ple, 10 ml were filtered using a 25-mm diameter filter
holder and a NucleoporeW filter with a 12-μm pore
size as previously described [17]. The filters were
placed on a glass slide and examined quantitativelyobium and S. mansoni based on the species name in the location.
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expressed as eggs/10 ml of urine. Infection intensities
were classified into two categories: (1) light infections
(<50 eggs/10 ml of urine) and (2) heavy infections
(≥50 eggs/10 ml of urine). For reducing the impact of
zero egg count and normalization of the data the geo-
metric mean of egg output was calculated in infected
children only.
In the first survey, stool samples were examined for S.
mansoni eggs and other helminths using the modified
Kato technique for a single stool sample.Treatment
Treatment was given not only to the children in the
three schools that were involved in the surveys, but to
the entire children in all elementary schools in the whole
district (18 schools). Treatment was carried out by
health teams of trained nurses and medical officers as
part of the treatment campaign. The study team assisted
this health team with treatment and also recorded and
observed the treatment of the study schoolchildren. All
schoolchildren were treated for schistosome infection
with a single dose of 40 mg/kg PZQ, without consider-
ing the infection status, 600 mg PZQ tablets, which can
be subdivided into four segments of 150 mg were used.
The health team provided a dosing sheet that showed
the correct dosage for different body weights. Children
infected with other helminthes received albendazole
orally.Data analysis
Data were entered into the computer using SPSS for
windows version 16.0 (SPSS Inc., Chicago, Illinois,
USA) and double checked before analysis. The chi-
square test was used to compare the differences in the
prevalence (proportions) of infection. Student t-test
was used to compare differences in the intensity of in-
fection (eggs/10 ml of urine). A value of P< 0.05 was
regarded as significant. Reduction in the prevalence
and intensity (egg count in eggs/10 ml of urine) was
calculated using the formulae below [18].
Ethics
The study received ethical clearance from the Research
Board of Communicable Disease, Ministry of Health,Prevalence reduction ¼ %prevalence before treatmenð
= %prevalence bð
Reduction in the intensity ¼ ðmean eggs=10ml of urine
mean egg
= mean eggs=10ðSudan. The trial was registered under ClinicalTrials.gov
NCT01558336Results
Of 562 (309 boys and 253 girls) schoolchildren enrolled
at baseline from the three schools, 420 were successfully
traced and re-examined at baseline and followed up with
two survey results for longitudinal parasitological data
on S. haematobium. There was no significant difference
in the data of children who dropped-out or missed the
follow-up survey to those included in both surveys (data
not shown). The mean age of these 562 children was
9.7 years (range, 6–15 years). Because few cases of S.
mansoni (2.3%), Hymenolepis nana (1.5%), hookworm
(1.1%), Trichuris trichiura (1.1%), and Ascaris lumbri-
coides (0.01%) were detected in the first survey, stool
examination was not conducted in the second survey.
Table 1 summarizes the parasitological results of S.
haematobium infection in the children from three
schools examined at baseline and 1 year after treatment.
The prevalence of S. haematobium infection ranged
from 38.5 to 59.2 1% with an overall prevalence of
51.4%, egg counts ranged from 71.7 to 104.4 eggs/10 ml
of urine with a mean of 87.7 eggs/10 ml of urine among
all children.
While there was no significant difference in prevalence
of infection between boys and girls (P = 0.228), boys had
significantly higher intensity of S. haematobium infec-
tion than girls (P< 0.001, Table 2). Children of< 10 years
of age had a significantly higher rate of prevalence
(P = 0.001) and intensity of S. haematobium infection (P
< 0 .001) than those children ≥ 10 years of age, (Table 3)
A single dose of PZQ significantly reduced the preva-
lence of S. haematobium infection by 83.3% (from 51.4%
to 8.6%) and the intensity of infection by 17.0% (from
87.7 to 72.8 eggs/10 ml of urine) 1 year after treatment.
While there was no significant difference in the reduc-
tion of the prevalence of S. haematobium infection be-
tween genders (P = 0.967) or age groups (P = 0.096),
there was a significantly higher reduction of intensity of
S. haematobium infection among girls in comparison
with boys (P = 0.001, Table 2 and Table 3). There was no
significant difference in the reduction of intensity among
different age groups. Interestingly, the reduction in
prevalence was not significantly different in children
with heavy or light infections Table 4.t %prevalence 1 year after treatmentÞ
efore treatmentÞ  100%:
before treatment
s=10ml of urine 1 year after treatmentÞ
ml of urine before treatmentÞ  100%:
Table 1 The prevalence and intensity of S. haematobium infections in children from three schools in Al Salamania in
Central Sudan
Base line One year post-treatment
School Children Examined Prevalence Intensity Children Examined Prevalence Intensity
n (%) %(95% CI) (95% CI) n (%) % (95% CI) (95% CI)
AbHaraz 157 (27.9) 59.2 86.9 153 (36.4) 13.1 73.3
51.4─66.7 86.0─87.8 8.4─19.1 71.6─74.5
Karni 223 (39.7) 56.5 104.4 147 (35.0) 9.5 87.7
50.0 ─62.0 103.4─105.4 5.5─15.1 84.7─90.7
El Dhiaga 182 (32.4) 38.5 71.7 (28.6)20 1.7 57.5
31.6─45.7 71.0─72.5 1 0.3─5.3 21.5─93.4
Total 562 (100) 51.4 87.7 420 (100) 8.6 72.8
47.3─55.5 87.3─88.1 6.2─11.5 71.5─74.1
P* 0.001 < 0.001 0.042 < 0.001
*P values indicate the difference between the schools.
Ahmed et al. Parasites & Vectors 2012, 5:108 Page 4 of 7
http://www.parasitesandvectors.com/content/5/1/108Discussion
The main findings of the current study are; high preva-
lence and intensity of S. haematobium among these chil-
dren, especially boys and among those less than ten
years of age, a significant reduction in prevalence [83.3%
(from 51.4% to 8.6%)] and intensity of S. haematobium
infection [17.0% (from 87.7 to 72.8 eggs/10 ml of urine)]
1 year after PZQ treatment. While there was no signifi-
cant difference in reduction of prevalence of S. haemato-
bium infection between gender, age groups or level of
infection, there was a significantly higher reduction of
intensity of S. haematobium infection among girls in
comparison to boys. The prevalence and intensity of in-
fection of S. haematobium in this setting indicates that
according to WHO criteria, regular treatment of school-
children in the area is indeed necessary [12].
The different age patterns for prevalence of infection
of S. haematobium and differences in infection intensity
observed in boys might indicate different water contact
patterns.Table 2 The prevalence, intensity and reduction of S. haemat
Salamania in Central Sudan at baseline and 1 year post treat
Variable Total
Base line
Children examined, n (%) 562 (100)
Prevalence,% (95% CI) 51.4(47.3─55.5)
Intensity, (95% CI) 87.7(87.2─88.1)
One year post treatment
Children examined, n (%) 420 (100)
Prevalence,% (95% CI) 8.6(6.2─11.5)
Intensity, (95% CI) 72.8(71.5─74.1)
Reduction in the prevalence,% (95% CI) 83.3 (73.0─89.7)
Reduction in the intensity, (95% CI) 17.0 (10.8─24.0)Recently, Touré et al., [19] observed that a single
round of PZQ treatment significantly reduced preva-
lence of S. haematobium infection by 87% (from 59.6%
to 7.7%) and intensity of infection by 92.8% (from 94.2
to 6.8 eggs/10 ml of urine) two years post-treatment.
Moreover, the proportion of school-age children with
heavy S. haematobium infection decreased significantly
(from 25% before treatment to around 2–3%) two years
post-treatment. In Mozambique, two cohorts of S. hae-
matobium infected schoolchildren were followed up two
months after PZQ treatment. The prevalence of infec-
tion decreased from 54.2% and 51.7% in high and low
transmission seasons to 30.3% and 1.8%, respectively.
The intensity of infection decreased from 23.3 eggs/
10 ml of urine at baseline to 15.6 eggs/10 ml of urine in
children treated during high transmission season, and
from 23.5 eggs/10 ml urine to 7.3 eggs/10 ml of urine
children treated during low transmission season [20]. In
Niger, three years after a single PZQ treatment, preva-
lence and intensity of S. haematobium infectionobium infections in children from three schools in Al
ment, relative to gender
Boys Girls P
309 (55.0) 253 (45.0)
53.7(48.1─59.2) 48.6(42.5─45.8) 0.228
101.4(100.6─102.1) 74.0 (72.2─74.8) <0.001
237(56.4) 183 (43.6)




Table 3 The prevalence, intensity and reduction of S. haematobium infections in children from three schools in Al
Salamania in Central Sudan at baseline and 1 year post treatment, relative to age
Variable Total Age< 10 years Age≥ 10 years P
Base line
Children examined, n (%) 562 (100) 275 (49.0) 287 (51.0)
Prevalence,% (95% CI) 51.4 (47.3─55.5) 58.2 (52.2─64.0) 44.9 (39.3─50.7) 0.001
Intensity, (95% CI) 87.7(87.2─88.1) 92.5 (91.8─93.1) 82.8 (82.1─83.4) <0.001
One year post treatment
Children examined, n (%) 420 (100) 205 (49.0) 215 (51.0)
Prevalence,% (95% CI) 8.6 (6.2─11.5) 9.8 (6.2─4.4) 7.4(4.4─11.6) 0.397
Intensity, (95% CI) 72.8 (71.5─74.1) 74.4 (72.6─76.2) 71.2 (69.3─73.1) 0.014
Reduction in the prevalence,% (95% CI) 83.3 (73.0─89.7) 83.3(74.3─90.0) 83.5(73.4-90.6) 0.096
Reduction in the intensity, (95% CI) 17.0 (10.8─24.0) 19.6(13.7─27.8) 14.0 (8.6─21.1) 0.327
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worth mentioning that different measures of intensity
(arithmetic mean of all positive and negative individuals)
were used in the other setting [22]; therefore the results
are not directly comparable with this study. Previous
reports from Khartoum, Sudan showed that PZQ treat-
ment of schoolchildren infected with S. haematobium
and/or S. mansoni was highly effective in terms of cure
rate (58%) and reduction (98%) in egg count six weeks
after the treatment [5].
We have recently shown that a single dose of PZQ
reduced the overall prevalence of S. mansoni infection
by 36.7% (from 59.1 to 37.4%) and the intensity of infec-
tion by 41.1% (from 116.7 to 68.7 eggs per gram of stool)
1 year after treatment. The reduction in prevalence was
significantly higher among the group of children with
heavy infections (by 76.1%, from 6.7 to 1.6%) and among
girls (by 54.1%, 42.3 to 19.4%) at 1 year after treatment
[16]. Because infections with S. haematobium are more
prevalent and generally more pathogenic in sub-Saharan
Africa [4], perhaps more PZQ should be used against S.
haematobium rather than S. mansoni, [4]. Evidence sug-
gests that S. haematobium is more sensitive to PZQ than
S. mansoni [23]. Yet, there are some reports of S. hae-
matobium infections that failed to respond to PZQ
[24,25].Table 4 Reduction in the prevalence of S. haematobium infec
Central Sudan, relative to the level of infections
Variable Total
Base line
Children examined, n (%) 562 (100)
Prevalence,% (95% CI) 51.4(47.3─55.5)
One year post treatment
Children examined, n (%) 420 (100)
Prevalence,% (95% CI) 8.6(6.2─11.5)
Reduction in the prevalence,% (95% CI) 83.3 (73.0─89.7)In the current study, there was no significant differ-
ence in reduction of prevalence of S. haematobium in-
fection between the levels of infection. Recent reports
showed that children lightly infected with S. haemato-
bium had a better cure rate than heavily infected chil-
dren [20]. Previously, Utzinger et al. and Raso et al.
[26,27] found an inverse relationship between cure rate
and intensity of infection in intestinal schistosomiasis. A
recent systematic review and meta-analysis showed that
praziquantel is an effective agent in schistosomiasis
treatment, and multiple doses might improve its efficacy
[28].
In schistosomiasis, infection intensity is a better indi-
cator of morbidity than prevalence as it reflects the
number of worms infecting the individual and it is also a
more reliable marker of treatment success defined as the
removal of egg-laying worms, which is usually the case
in treatment programs and larger epidemiological stud-
ies [18,29,30]. One of the limitations of the current study
is the use of single egg counts. A single egg count is a
less reliable tool for estimating prevalence and infection
status of schistosomiasis. The examination of two or
more specimens per child would have led to even higher
estimates of total prevalence and intensity. The other
limitation of the current work is lack of information on
seasonality of the transmission of S. haematobiumtions in children from three schools in Al Salamania in
Light infection Heavy infection Negative
137(24.4) 152 (27.0) 273 (48.6)
24.4 (21.0─28.0) 27.0 (23.5─30.8) ─
17(4.0) 19(4.5) 384 (91.4)
4.0 ( 2.4─6.3) 4.5 (2.8─6.8) ─
82.0 ( 63.1─93.7) 83.3 (70.8─91.4) ─
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response to PZQ treatment. Recent reports showed that
adults and preschool children were at risk of schisto-
somiasis and can contribute to the transmission [31,32];
therefore schistosomiasis control interventions should
also target these groups in addition to school children in
endemic areas.
Conclusion
There was a significant reduction of S. haematobium in-
fection 1 year after PZQ treatment in this setting.
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